Enhertu for Prostate Cancer
(CaRPET Trial)

Recruiting in Palo Alto (17 mi)

Overseen byEric Knoche, MD

Age: 18+

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: Washington D.C. Veterans Affairs Medical Center

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.

Eligibility Criteria

Men with advanced prostate cancer that has spread and is resistant to hormone therapy can join. They must have tried other treatments like hormone blockers or chemotherapy, keep taking drugs to lower testosterone, and have a confirmed diagnosis of adenocarcinoma. A tissue sample for testing if the cancer reacts to HER2 treatment is also needed.

Inclusion Criteria

My cancer has worsened despite hormone therapy and possibly chemotherapy.

My tumor sample is prepared for HER2 testing.

My prostate cancer is confirmed to be adenocarcinoma.

+2 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Enhertu as a subsequent line of therapy for HER2-positive metastatic castration-resistant prostate adenocarcinoma

24 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Participant Groups

The trial tests Enhertu in men whose prostate cancer has worsened despite previous treatments. It's specifically for those with HER2-positive tumors, which means their cancer cells have more of a certain protein that the drug targets.

1Treatment groups

Experimental Treatment

Group I: Enhertu for HER2 positive metastatic castrate resistant prostate cancerExperimental Treatment1 Intervention